Business Context and Reporting Period
Passage BIO, Inc. (PASG) filed a Form 8-K on September 4, 2024, reporting a material impairment event. The filing details a sublease agreement for approximately 3,200 square feet (5%) of its Hopewell, New Jersey laboratory space, executed in response to prior organizational redesigns and asset outlicenses announced in July 2023 and August 2024.
Key Financial Metrics
- Impairment Expense: The Company expects to recognize non-cash impairment expenses of approximately $3.5 million to $5.5 million in the quarter ending September 30, 2024.
- Sublease Revenue: The agreement generates a base rent of $0.1 million per year, increasing by 2.5% annually, with an option to extend through December 2032.
- Impact on Net Loss: Sublease income is expected to reduce the annualized net loss by approximately $0.1 million to $0.2 million compared to 2023 expenses.
- Liquidity: The impairment is non-cash and will not impact the cash runway. The Company expects existing cash, cash equivalents, and marketable securities to fund operations through the end of the second quarter of 2026.
Material Changes
The filing reports a reassessment of long-lived assets (right-of-use assets, leasehold improvements, and laboratory equipment) due to the sublease and corporate developments. This triggered an impairment charge under ASC 360. The filing does not provide specific revenue, profit, or debt figures for the current period, focusing solely on the impairment event and liquidity outlook.
Outlook, Risks, and Management Commentary
Management states the impairment range is preliminary, unaudited, and subject to change based on final financial statement completion and potential additional sublease agreements. The Company is actively pursuing opportunities to sublease additional space to further offset lease obligations. Forward-looking statements regarding cash runway and impairment timing are subject to risks detailed in the Company's Form 10-Q for the period ended June 30, 2024.
Investor Verification Checklist
- Verify the final impairment amount in the upcoming Q3 2024 financial statements, as the current $3.5M-$5.5M range is preliminary.
- Confirm the Company's cash balance and burn rate to validate the runway projection to Q2 2026.
- Monitor for announcements regarding additional sublease agreements for the remaining 95% of the laboratory space.
- Review the impact of the non-cash charge on the Company's GAAP net loss for the quarter.